High-Grade Non-Hodgkin's Lymphoma Stage I: A retrospective study of treatment, outcome and prognostic factors in 213 patients

Osterman, Birgitta; Cavallin‐Ståhl, Eva; Hagberg, Hans; Lindén, Ola; Lenner, Per

doi:10.3109/02841869609098498

Cited by 20 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty-nine per cent of the patients relapsed after a median follow-up of 5 years, 4% within the radiation field. The 5-year survival was comparable for nodal and extranodal lymphomas (19).…”

Section: Aggressive Non-hodgkin's Lymphomasmentioning

confidence: 79%

“…No randomized trial has been published since the previous report. In a Swedish non-randomized study from three institutions the relapse rate was higher in the radiotherapy group compared with the combined modality therapy group for patients in stage I/I E (29% vs. 15%, p0/0.05) (19). The median radiation dose was 44 Gy.…”

Section: Aggressive Non-hodgkin's Lymphomasmentioning

confidence: 99%

“…Á/ Although randomized and non-randomized studies favour combined modality treatment with chemotherapy followed by radiotherapy instead of radiotherapy or chemotherapy alone in localized disease no firm conclusions can be drawn (pro (19) Optimal dose for radiation alone or after chemotherapy has not been established.…”

Section: Aggressive Localized Lymphomasmentioning

confidence: 99%

See 2 more Smart Citations

A Systematic Overview of Radiation Therapy Effects in Non-Hodgkin's Lymphoma

2003

Self Cite

View full text Add to dashboard Cite

Section: Aggressive Non-hodgkin's Lymphomasmentioning

confidence: 79%

Section: Aggressive Non-hodgkin's Lymphomasmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Overview of Radiation Therapy Effects in Non-Hodgkin's Lymphoma

2003

Self Cite

View full text Add to dashboard Cite

“…Non-Hodgkin's lymphoma, including stage I H-NHL, typically is a disease of the elderly. Median age at presentation in 213 Swedish patients treated at regional centres was 67 years (3). A very large American study reported a median patient age of 65 years for patients with non-Hodgkin's lymphoma of all stages (2), while a British study on 243 stage I patients included in trials reported a median age of 56 years, re¯ecting patient selection (4).…”

Section: Original Articlementioning

confidence: 99%

Stage I High-Grade Non-Hodgkin's Lymphoma

Lote

Holte²,

Nome³

et al. 2000

Acta Oncologica

View full text Add to dashboard Cite

We report long-term survival and prognostic factors in 252 patients with stage I high-grade lymphoma. Median patient age was 64 years and 49% of patients had extranodal lymphoma. Premenopausal women had less risk of extranodal lymphoma than older women or males (p < 0.002). Disease specific 5 and 15 years' survival in patients < 64 years was 83% and 76%, respectively; compared to 54% and 46% in patients > 64 years of age. Age, non-centroblastic histology, B-symptoms, and increased serum lactate dehydrogenase (LDH) were independently negative prognostic factors (p < 0.01), while extranodal, testicular, or bulky ( > 6 cm) lymphoma presentation were of no prognostic significance. A radiation dose of 40 Gy in 2 Gy fractions to the primary site prevented in-field relapse in 159 of 173 irradiated patients (92%) and only three of 173 patients (1.7%) had local relapse in the absence of systemic dissemination.

show abstract

“…Previous studies have shown that almost 70% of patients with localized NHL can be cured by RT alone [9,10]. However, the high relapse rate outside the radiation field justifies the requirement of chemotherapy in this setting [11,12]. …”

Section: Introductionmentioning

confidence: 99%

Is there a role for consolidative radiotherapy in the treatment of aggressive and localized Non-Hodgkin Lymphoma? A systematic review with meta-analysis

Santos

Lima

et al. 2012

BMC Cancer

View full text Add to dashboard Cite

Background Chemotherapy is the mainstay of non-Hodgkin lymphoma (NHL) treatment. Based on expert opinion, the use of radiotherapy (RT) is currently preferred in some institutions as consolidative treatment for patients with localized disease. The lack of conclusive data coming from conflicting studies about the impact of treatment demands a systematic review, which could provide the most reliable assessment for clinical decision-making. We evaluate the addition of RT post-CT, for aggressive and localized NHL (ALNHL). Methods Randomized controlled trials (RCT) that evaluated chemotherapy alone versus chemotherapy plus RT were searched in databases. The outcomes were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity. Risk ratio (RR) and hazard ratio (HR) with their respective 95% confidence intervals (CI) were calculated using a fized-effect model. Results Four trials (1,796 patients) met the inclusion criteria. All trials tested the use of RT after systemic therapy comprising anthracycline-based chemotherapy. This systematic review showed that RT enhances PFS after chemotherapy (hazard ratio [HR] 0.81; 95% CI 0.67-0.98; p = 0.03), with no impact on ORR and OS. Some heterogeneity between trials could limit the conclusions about OS. Toxicity data could not be pooled due to differences in reporting adverse events. Conclusions This systematic review with meta-analysis shows no improvement in survival when adding RT to systemic therapy for ALNHL. Our conclusions are limited by the available data. Further evaluations of new RT technologies and its association with biologic agents are needed.

show abstract

High-Grade Non-Hodgkin's Lymphoma Stage I: A retrospective study of treatment, outcome and prognostic factors in 213 patients

Cited by 20 publications

References 32 publications

A Systematic Overview of Radiation Therapy Effects in Non-Hodgkin's Lymphoma

A Systematic Overview of Radiation Therapy Effects in Non-Hodgkin's Lymphoma

Stage I High-Grade Non-Hodgkin's Lymphoma

Is there a role for consolidative radiotherapy in the treatment of aggressive and localized Non-Hodgkin Lymphoma? A systematic review with meta-analysis

Contact Info

Product

Resources

About